Danaher Corporation $DHR Stock Holdings Decreased by Fiduciary Alliance LLC

Fiduciary Alliance LLC lessened its position in Danaher Corporation (NYSE:DHR) by 16.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 29,691 shares of the conglomerate’s stock after selling 5,772 shares during the quarter. Fiduciary Alliance LLC’s holdings in Danaher were worth $5,886,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DHR. Ceredex Value Advisors LLC boosted its holdings in shares of Danaher by 1.6% during the second quarter. Ceredex Value Advisors LLC now owns 249,377 shares of the conglomerate’s stock worth $49,262,000 after purchasing an additional 3,862 shares during the period. Chicago Capital LLC lifted its position in Danaher by 11.6% in the 2nd quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock worth $2,634,000 after buying an additional 1,391 shares in the last quarter. Weitz Investment Management Inc. lifted its position in Danaher by 6.1% in the 2nd quarter. Weitz Investment Management Inc. now owns 526,950 shares of the conglomerate’s stock worth $104,094,000 after buying an additional 30,300 shares in the last quarter. UniSuper Management Pty Ltd boosted its stake in shares of Danaher by 1.6% during the 1st quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock valued at $34,954,000 after buying an additional 2,667 shares during the period. Finally, Nvwm LLC grew its holdings in shares of Danaher by 20.4% during the 2nd quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock valued at $1,401,000 after acquiring an additional 1,204 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Performance

Shares of NYSE DHR opened at $222.91 on Thursday. The business’s 50-day simple moving average is $219.53 and its 200-day simple moving average is $206.53. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $258.23. The firm has a market cap of $157.45 billion, a price-to-earnings ratio of 45.96, a P/E/G ratio of 4.36 and a beta of 0.89.

Danaher (NYSE:DHR) last announced its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. During the same quarter in the prior year, the business earned $1.71 earnings per share. The company’s revenue was up 4.4% on a year-over-year basis. As a group, equities research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be paid a $0.32 dividend. The ex-dividend date is Friday, December 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s dividend payout ratio (DPR) is presently 26.39%.

Analysts Set New Price Targets

DHR has been the topic of a number of research reports. Redburn Partners set a $220.00 price target on shares of Danaher in a research note on Wednesday, October 8th. Cowen reaffirmed a “buy” rating on shares of Danaher in a research note on Wednesday, October 22nd. Morgan Stanley initiated coverage on Danaher in a report on Monday, December 1st. They set an “overweight” rating and a $270.00 price target for the company. The Goldman Sachs Group initiated coverage on Danaher in a report on Tuesday, December 9th. They issued a “buy” rating and a $265.00 price objective on the stock. Finally, Evercore ISI lifted their target price on shares of Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Twenty investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $248.25.

Insider Buying and Selling

In other news, SVP Georgeann Couchara sold 5,174 shares of Danaher stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the transaction, the senior vice president directly owned 2,625 shares in the company, valued at approximately $552,352.50. The trade was a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the transaction, the senior vice president directly owned 14,553 shares of the company’s stock, valued at $3,190,454.19. This represents a 59.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 30,248 shares of company stock worth $6,609,663 in the last quarter. 11.10% of the stock is currently owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.